-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Laurent Garderet, MD, PhD1, Mohammad Al Hariri2*, Joanna Wasielica-Poslednik2*, Markus Munder3*, Kitti Kormányos4*, Camila Peña, MD5, Alessandro Gozzetti6*, Xiang Zhou7,8,9*, Anna Waszczuk-Gajda, MD10*, Laura Rosinol11*, Gabor Mikala, MD, PhD12*, Mateusz Krzystanski13*, Walter Lisch2*, David H. Vesole, MD, PhD14, Nora Szentmáry15* and Artur Jurczyszyn, MD16*

1Service Hematologie, Sorbonne Université, Hopital Pitié Salpêtière APHP, Paris, France
2Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, Mainz, Germany
3Department of Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
4Department of Ophthalmology, Semmelweis University, Budapest, Hungary, Budapest, Hungary
5Hematology Department, Hospital Del Salvador, Santiago, Chile
6Policlinico Le Scotte University of Siena, Siena, Italy
7Department of Internal Medicine II, Division of Oncology and Hematology, University Hospital Wuerzburg, WüRzburg, Germany
8Department of Internal Medicine II, Hematology and Oncology, University Hospital of Würzburg, Wurzburg, Germany
9Department of Internal Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
10Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
11Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
12Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary
13Plasma Cell Dyscrasia Center, Department of Hematology, Jagiellonian University Medical College, Krakow, Poland, Krakow, Philippines
14John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
15Department of Ophthalmology, Semmelweis University, Budapest, Hungary 13 Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Aniridia Research, Homburg/Saar,, Budapest, Hungary
16Department of Hematology, Jagiellonian University Medical College, Cracow, Poland

Sheila K Pierson, MSc1*, Russell Perkins2*, Frits van Rhee, MD PhD3, Corey Casper, MD, MPH4* and David C Fajgenbaum, MD, MBA, MSc2

1Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
4Infectious Disease Research Institute, Seattle, WA

Arata Ishii1,2*, Shokichi Tsukamoto, MD, PhD1,2, Naoya Mimura, MD, PhD1,3, Yurie Nagai, MD, PhD4*, Shinichiro Matsui, MD1*, Sanshiro Nakao, MD1*, Asuka Shibamiya, MD1*, Yutaro Hino, MD, PhD1*, Kensuke Kayamori, MD, PhD1*, Nagisa Oshima-Hasegawa, MD, PhD1*, Tomoya Muto, MD, PhD1,2, Shio Mitsukawa, MD, PhD1,3*, Yusuke Takeda, MD, PhD1*, Tomoki Suichi, MD, PhD5*, Sonoko Misawa, MD, PhD5*, Chikako Ohwada, MD, PhD1,6, Koutaro Yokote, MD, PhD2*, Satoshi Kuwabara, MD, PhD5*, Chiaki Nakaseko, MD, PhD6, Hiroyuki Takamatsu, MD, PhD7 and Emiko Sakaida, MD, PhD1,2,3

1Department of Hematology, Chiba University Hospital, Chiba, Japan
2Department of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan
3Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan
4Department of Hematology, Oami Hospital, Chiba, Japan
5Department of Neurology, Chiba University Hospital, Chiba, Japan
6Department of Hematology, International University of Health and Welfare, Narita, Japan
7Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Shaji K Kumar, MD1, Nnadozie Emechebe, MPH2*, Jin Lu, MD3, Yang Liu, PhD4*, Max Bittrich, MD5,6, Juan Du, MD, PhD7*, Hartmut Goldschmidt8, Charalampia Kyriakou, MD, PhD9, Donna E. Reece10,11, Kihyun Kim, MD12, Maria-Victoria Mateos13, Veronica Gonzalez De La Calle, MD, PhD14*, Wenming Chen, MD, PhD15*, Heinz Ludwig, MD16,17, Giampaolo Merlini, MD18, Silvia Mangiacavalli, MD19*, Meletios A. Dimopoulos, MD20, Efstathios Kastritis, MD21*, Chang-Ki Min, M.D., Ph.D.22*, Graca Esteves, MD23,24*, Hiroshi Handa, MD, PhD25, Fernando Escalante, MD26*, Carlos Fernandez de Larrea, MD, PhD27, Michel Delforge28, Andrew J. Yee, MD29, Noopur S. Raje, MD29, Sudeep Karve30*, Emma Arriola, PhD31, Robert F. Cornell, MD32 and Brian G.M. Durie, MD33

1Department of Hematology, Mayo Clinic Rochester, Rochester, MN
2AbbVie, Inc., North Chicago, IL
3Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China
4Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Beijing, China
5Universitätsklinikum Würzburg, Würzburg, Germany
6Universitätsklinikum Würzburg, Wuerzburg, DEU
7The myeloma & lymphoma Cancer Center, Shanghai Changzheng hospital, Naval Medical University, Shanghai, China
8University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany
9University College London Hospital, UCLH Centre for Waldenström and Related Conditions, London, United Kingdom
10Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
11Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
12Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan Univ. Sch. of Med. Samsung Medical Center, Seoul, South Korea
13Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
14Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
15Beijing Chao-Yang Hospital of Capital Medical University, Beijing, China
16Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
17Wilhelminenspital, Vienna, Austria
18Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
19Division of Hematology, IRCCS Fondazione Policlinico San Matteo Pavia, Pavia, Italy
20National and Kapodistrian University of Athens, Athens, Greece
21Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
22Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
23PETHEMA, Lisboa, Portugal
24Department of Hematology and Marrow Transplantation, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Lisbon, Portugal
25Department of Hematology, Gunma University Hospital, Maebashi, Japan
26Department of Hematology, Hospital Universitario de Leon, Leon, Spain
27Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
28University Hospital Leuven, Leuven, Belgium
29Massachusetts General Hospital Cancer Center, Boston, MA
30Abbvie Inc., North Chicago, IL
31Abbvie, Maidenhead, GBR
32Division of Hematology and Oncology, Vanderbilt Univ. Medical Center, Nashville, TN
33Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA

Matthew W Jenner1*, Andrew Hall2*, Sian E Faustini, PhD3*, Alexandra Pitchford2*, Ruth M. de Tute, PhD, FRCPath4*, Sadie Roberts2*, Emma Ingleson5*, Kristian M Bowles, MBBS, PhD6, Mamta Garg, MD, FRCP, FRCPath7*, Anand Lokare, MD, FRCPath, MRCP8*, Christina Messiou9*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM10, Guy Pratt, MD FRCP FRCPath11, Gordon Cook, MB ChB, PhD2*, Roger G Owen, MD12*, Sarah R Brown, PhD, MSc, BSc2*, Mark T Drayson, MD13* and Martin F. Kaiser, MD, FRCP, FRCPath9,14

1Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
2Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
3Birmingham University, Birmingham, United Kingdom
4Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom
5Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom
6Norwich Medical School, University of East Anglia, Norwich, United Kingdom
7Leicester Royal Infirmary, Leicester, United Kingdom
8Department of Haematology, Heartlands Hospital, University Hospitals Birmingham, Birmingham, United Kingdom
9The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
10Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom
11Centre for Clinical Haematology, University Hospital Birmingham, Birmingham, United Kingdom
12St. James's University Hospital, Leeds, United Kingdom
13Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
14The Institute of Cancer Research, London, United Kingdom

Maryam Omar, BS1, Rahma M Warsame, MD2, Morie A. Gertz, M.D.2, Francis K. Buadi, MB, CHB3*, Ronald Go, MD2, Shaji K Kumar, MD2, David Dingli, M.D., Ph.D.2, Robert A. Kyle, MD2, Nelson Leung, MD4, Taxiarchis Kourelis, M.D.2, Suzanne R. Hayman, M.D.2, Yi Lin5, Martha Q. Lacy, MD4, John A. Lust, MD, PhD2, Yi L. Hwa, NP2, Amie Fonder, PA-C, MS2*, Prashant Kapoor, MD2, Miriam A. Hobbs, APRN, CNP, DNP2*, Wilson I Gonsalves, MD6, S. Vincent Rajkumar, MD7*, Eli Muchtar, MD8, Alissa Visram, MD2, Stephen J. Russell, MD, PhD9 and Angela Dispenzieri, MD2

1Mayo Clinic Alix School of Medicine, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN
3Mayo Clinic Rochester, Division of Hematology, Rochester, MN
4Division of Hematology, Mayo Clinic Rochester, Rochester, MN
5Mayo Clinic, Rochester, MN
6Division of Hematology, Mayo School of Graduate Medical Education, Rochester, MN
7Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
8Division of Hematology, Mayo Clinic Rochester, Saint Paul, MN
9Department of Molecular Medicine, Mayo Clinic, Rochester, MN

Xavier Leleu, MD1, Mario Boccadoro2*, Hans C. Lee, MD3, Jeffrey A. Zonder, MD 4, Magaret Macro5*, Karthik Ramasamy, MD6, Cyrille Hulin7*, Jiri Silar, MSc8*, Matyáš Kuhn, MSc8*, Kaili Ren, PhD9*, Nawal Bent-Ennakhil10*, Sylvie Bouillie11*, Dasha Cherepanov9*, Dawn Marie Stull12* and Evangelos Terpos, MD, PhD13

1Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France
2Division of Hematology, University of Torino, Torino, Italy
3M.D. Anderson Cancer Center, Houston, TX
4Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI
5CHU de Caen, Caen, France
6Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
7CHU de Bordeaux, Bordeaux, France
8Institute of Biostatistics & Analyses, Ltd, Brno, Czech Republic
9Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
10Takeda Pharmaceuticals International AG, Opfikon, Switzerland
11Takeda France SAS, Paris, France
12Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
13Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Nicola Sgherza1*, Paola Curci, MD1*, Rita Rizzi, MD2*, Silvio Tafuri, MD3*, Pasquale Stefanizzi, MD3*, Vanda Strafella, MD2*, Daniela Di Gennaro, MD2*, Angelantonio Vitucci, MD1*, Antonio Palma, MD1*, Antonella Vita Russo Rossi, MD1*, Luigi Vimercati, MD4*, Francesco Albano, MD2* and Pellegrino Musto, MD1,2

1Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy
2Department of Emergency and Organ Transplantation, “Aldo Moro” University School of Medicine, Bari, Italy
3Department of Biomedical Science and Human Oncology, “Aldo Moro” University School of Medicine, Bari, Italy
4Interdisciplinary Department of Medicine, "Aldo Moro" University School of Medicine, Occupational Medicine Unit, AOUC Policlinico, Bari, Italy

Leonie Abbink1*, Mirian Brink, PhD2*, Wilfried Roeloffzen3*, Pino Poddighe, MD, PhD4* and Monique C. Minnema, MD5

1Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands, Utrecht, Netherlands
2Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands, Utrecht, Netherlands
3Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
4Department of Human Genetics Amsterdam UMC, Amsterdam University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
5UMC Utrecht, Utrecht, Netherlands

Oliver Van Oekelen, MD, MSc1,2,3, Tarek H. Mouhieddine, MD4, Darren Pan, MD, BS5*, Megan Metzger, MD6*, Sarita Agte, MD2*, Adolfo Aleman, MPA2,3,5*, David T. Melnekoff, MS1,2,7*, Guido Lancman, MD2,5, Alessandro Lagana, PhD2,8*, Shambavi Richard2,5*, Larysa Sanchez, MD2,5*, Joshua Richter, MD2,5, Hearn Jay Cho, MD, PhD2,5,9, Ajai Chari, MD5,10*, Sundar Jagannath, MD2,5* and Samir Parekh, MD2,5,11,12

1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
3Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
5Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
6Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
7Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
8Department of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, NY
9Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
10Mount Sinai, New York, NY
11Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
12Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Feng Wang, PhD, MPH, BSM1*, Boris Gorsh, PharmD2*, Maral DerSarkissian, PhD3*, Prani Paka, PharmD2*, Rachel Bhak, MS3*, Natalie Boytsov, PhD2*, Miriam L. Zichlin, MPH3*, Leah Sansbury, PhD, MSPH1*, Christopher W. Yee, MS3*, Shannon Ferrante, PhD2*, Anamika Khanal, BA3*, Ahmed Noman, BA3* and Mei Sheng Duh, ScD, MPH3

1GlaxoSmithKline, Research Triangle Park, NC
2GlaxoSmithKline, Upper Providence, PA
3Analysis Group, Inc., Boston, MA

Charanpreet Singh, MD, MBBS1*, Sreejesh Sreedharanunni, MBBS, MD, DM2*, Vandana Panakkal3*, Aditya Jandial, MD, MBBS4*, Arihant Jain4*, Deepesh Lad, MD, DM4, Gaurav Prakash, MD, DM4*, Alka Khadwal, MD4* and Pankaj Malhotra, MD4

1Department of Internal Medicine, Chandigarh, India
2Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3Postgraduate Institute of Medical Education and Research, Chandigarh, IND
4Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Nadine Abdallah, MD1*, David L Murray, MD, PhD2*, Angela Dispenzieri, MD3, Prashant Kapoor, MD1, Morie A. Gertz, M.D.1, Martha Q. Lacy, MD4, Suzanne R. Hayman, M.D.1, Francis K. Buadi, MB, CHB5*, Wilson I Gonsalves, MD1, Eli Muchtar, MD1*, Nelson Leung, MD4, David Dingli, M.D., Ph.D.1, Taxiarchis Kourelis, M.D.1, Rahma M Warsame, MD1, Moritz Binder, MD, MPH1*, Robert A. Kyle, MD1, S. Vincent Rajkumar, MD1* and Shaji K Kumar, MD3

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
3Mayo Clinic, Rochester, MN
4Division of Hematology, Mayo Clinic Rochester, Rochester, MN
5Mayo Clinic Rochester, Division of Hematology, Rochester, MN

Maria Moscvin1*, Christine Ivy Liacos, MSc2*, Tianzeng Chen, MS3*, Foteini Theodorakakou, MD4*, Despina Fotiou, MD4*, Eileen Regan, DNP5*, Efstathios Kastritis, MD6*, Meletios A. Dimopoulos, MD7, Paul G. Richardson, MD8 and Giada Bianchi, MD3

1Brigham and Women's Hospital, Boston, MA
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
3Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
4Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5Dana Farber Cancer Institute, Boston, MA
6Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
7National and Kapodistrian University of Athens School of Medicine, Athens, Greece
8Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA

Freda R Coren1*, Mateo Sarmiento Bustamante2*, Sheila K Pierson, MSc3* and David C Fajgenbaum, MD, MBA, MSc2

1Center for Cytokine Storm Treatment & Laboratory (CSTL), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Mina Dehghani, MD1, Shona Philip, BSc, MD2, Anthony Quint, MSc (Stats and Math)3*, Lenicio Siqueira4*, Selay Lam, MD, BSc, FRCPC5, Chai Wye Phua, MD, FRCPC6, Anargyros Xenocostas, MD, FRCPC7,8, Uday Deotare, MBBS, MD, DM8* and Martha L Louzada, MD, MSc9,10,11,12,13

1University of Toronto, Sunnybrook Hospital, Odette cancer center, University of Toronto, Sunnybrook hospital, London, ON, Canada
2Bone Marrow Transplant Program, Stanford University Medical Center, London, ON, Canada
3London Health Sciences Centre, McGill Universtiy, London, ON, Canada
4Department of Medicine, Division of Hematology, Schulich School of Medicine & Dentistry, Western University, London, Canada
5Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London Health Sciences Centre, London, ON, Canada
6Department of Medicine, Division of Hematology, Western University, London Health Sciences Centre, London, ON, Canada
7Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
8Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada
9Canvector member, Canadian Myeloma Research Group (CMRG), London, ON, Canada
10University of Western Ontario, London Health Sciences Centre, London, ON, Canada
11Hematology, University of Western Ontario -London Health Sciences Centre, London, ON, Canada
12Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada
13Medical Oncology, London Regional Cancer Centre, London, ON, Canada

Jithma P. Abeykoon, MD1, Luliana Vaxman2*, Sanjay V Patel2*, Shaji K Kumar, MD3, Kimberly S Young2*, Sikander Ailawadhi, MD4, Jeremy T. Larsen5, Wilson I Gonsalves, MD6, Taxiarchis Kourelis, M.D.1, Nelson Leung, MD7, Rahma M Warsame, MD1, Miriam A. Hobbs, APRN, CNP, DNP1*, Amie Fonder, PA-C, MS1*, Yi L. Hwa, NP1, P. Leif Bergsagel, MD8, Martha Q. Lacy, MD7, S. Vincent Rajkumar, MD1*, Morie A. Gertz, M.D.1 and Prashant Kapoor, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Mayo Clinic, Rochester
3Mayo Clinic, Rochester, MN
4Division of hematology, Mayo Clinic, Jacksonville, FL
5Division of Hematology, Mayo Clinic, Phoenix, AZ
6Division of Hematology, Mayo School of Graduate Medical Education, Rochester, MN
7Division of Hematology, Mayo Clinic Rochester, Rochester, MN
8Division of Hematology, Mayo Clinic, Scottsdale, AZ

Samuel D. Stampfer, MD, PhD1*, Marissa-Skye Goldwater, BS2*, Bernard Sean S. Regidor, BS3*, Scott Kristian Jew, BS2,3*, Sean Elliott Bujarski, BA2,3*, Haiming Chen, MD, PhD2, David Yashar, MD3,4*, Ning Xu, PhD2*, Mingjie Li, BS2*, Tracy Green3*, Eddie Fung, BS3*, Elias Aquino3*, Regina Swift3*, Shahrooz Eshaghian, MD5, Aaron Feinstein, MD6* and James R. Berenson, MD2,3,7,8

1Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA
2Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
3Berenson Cancer Center, West Hollywood, CA
4Harbor-UCLA Medical Center, Torrance, CA
5Compassionate Hematology & Oncology, Los Angeles, CA
6Cedars-Sinai Medical Center, Tarzana, CA
7Oncotherapeutics, West Hollywood, CA
8OncoTracker, West Hollywood, CA

Naveen K Yarlagadda1*, Meera Mohan, MD2, Shebli Atrash, MD3, Sravani Gundarlapalli4*, Shadiqul Hoque, MD5*, Sunil Kakadia, MD6*, Sharmilan Thanendrarajan, MD7, Carolina Schinke, MD7, Daisy Alapat1*, Guido Tricot, MD, PhD7, Erming Tian, PhD, MBA8, Jeffery R. Sawyer9*, Fenghuang Zhan, MD. PhD10, Frits van Rhee, MD PhD7 and Maurizio Zangari, MD, FACP7

1UAMS, Little Rock, AR
2Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
4University of Arkansas for Medical Sciences, Little rock
5Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
6University of Arkansas for Medical Sciences, Little Rock, AR
7Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
8Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas For Medical Sciences, Little Rock, AR
9Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
10Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer InstituteMyeloma Center, Division of Hematology and Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Ariel Siegel1*, Eileen M Boyle, MD, PhD2, Patrick Blaney, MS3*, Yubao Wang, PhD4*, Hussein Ghamlouch1*, Jinyoung Choi, PhD5*, Jessica Caro, MD2, Louis Williams, MD6, Beatrice Razzo, MD7, Arnaldo A. Arbini, MD8*, Marc Braunstein9*, David Kaminetzky9*, Daniel Auclair10*, Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, FRCPath11, David Cairns, PhD12*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM13, Brian Walker14*, Benedetto Bruno, MD, PhD15*, Gareth J. Morgan, MD, PhD9 and Faith E. Davies, MD6

1NYU Langone Health, Myeloma Research Program, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
2Perlmutter Cancer Center, New York University Langone Health, New York, NY
3Perlmutter Cancer Center, NEW YORK UNIVERISITY, New York, NY
4Perlmutter Cancer Center,, Myeloma Research Program, New York, NY
5Myeloma Research Program, Laura and Isaar Perlmutter Cancer Center, NEW YORK UNIVERSITY, New York, NY
6Laura & Isaac Perlmutter Cancer Center, NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY
7Myeloma Research Program, NYU Langone's Perlmutter Cancer Center, New York, NY
8NYU Langone Medical Center, New York, NY
9Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
10The MMRF, Norwalk, CT
11Institute of Cancer Research, Sutton, United Kingdom
12Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
13Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
14Division of Hematology Oncology, Melvin and Bren Simon Comprehensive Cancer Center,, Indianapolis, IN
15Blood and Marrow Transplantation and Cellular Therapy, New York University Langone Health, New York, NY

Diana Zhang, MD1*, Danai Dima, MD2*, Mumtu Lalla, MD1*, Denis Toskic, BS3*, Ping Zhou, MD, PhD4*, Amandeep Godara, MD5 and Raymond Comenzo, MD6

1Department of Medicine, Tufts Medical Center, Boston, MA
2Department of Internal Medicine, Tufts Medical Center, Boston, MA
3Tufts Medical Center, Boston
4John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
5Department of Hematology/Oncology, University of Utah, Salt Lake City, UT
6Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

Jiri Minarik, MD1, Jakub Radocha, MD, PhD2*, Alexandra Jungova, MD, PhD3*, Jan Straub, MD4*, Tomas Jelinek5, Tomas Pika, MD, PhD6*, Ludek Pour, MD7*, Petr Pavlicek, MD8*, Lubica Harvanova9*, Lenka Capkova10*, Petra Krhovska, MD1*, Katerina Machalkova11*, Pavel Jindra, MD, PhD12*, Ivan Spicka, MD, Prof, PhD13*, Hana Plonkova14*, Martin Stork7*, Martin Mistrik, MD, PhD15, Jaroslav Bacovsky16*, Vladimir Maisnar, MD, Prof, PhD, MBA17* and Roman Hajek, MD, PhD5

1Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
2Department of Clinical Hematology, University Hospital, Hradec Kralove, Hradec Kralove, CZE
3Hematology and Oncology Department, Charles University Hospital in Pilsen, Pilsen, Czech Republic
41st Medical Department – Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
5Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
6Department of Hematooncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
7Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
8Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
9Department of Hematology and Transfusiology, Faculty of Medicine, University Hospital Bratislava,, Bratislava, Slovakia
10Institute of biostatistics and analyses, Ltd., Brno, Czech Republic
114th Department of Internal Medicine – Hematology,, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
12University Hospital Pilsen, Pilsen, Czech Republic
13Charles University and General Hospital, Prague, Czech Republic
14Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
15Department of Hematology and Transfusiology, Univ. Hosp., Bratislava, Slovakia
16Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
174th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Králové, Czech Republic

Scott Soefje1*, Corinne Carpenter2*, Katherine Carlson2*, Samir Awasthi2*, Thomas S. Lin, MD, PhD3, Shuchita Kaila, PhD3*, Daniel Tarjan2*, Nikhil Kayal2*, Christian Kirkup2*, Tyler Wagner2*, Kathleen Gray, PhD3* and Shaji K Kumar, MD1

1Department of Hematology, Mayo Clinic Rochester, Rochester, MN
2nference, Cambridge, MA
3Janssen Scientific Affairs, LLC, Horsham, PA

Liye Zhong1*, Yongqiang Wei2*, Baohong Ping3*, Xin Li4, Hongling Peng5*, Yongqain Li6*, Yuyang Tian, MM7*, Zelin Liu8*, Jun Luo, DO9*, Yongzhong Su10*, Haifei Chen11*, Yanjuan He12*, Hongliang Li13*, Congming Wu14*, Zhiqiang Sun, MD, PhD15*, Keqian Shi, MD16*, Xiaoliang Li17*, Qing Zhang, MD18, Guoyu Hu19*, Gang Huang20*, Zhenqian Huang, MD21*, Weida Wang, MD, PhD22* and Zhongjun Xia, MD, PhD23

1Guangdong Provinal People's Hospital, Guangzhou, China
2Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3Department of Hematology, Hui qiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
4Department of Hematology, the Third Xiangya Hospital; Central South University, Changsha, China
5Division of Hematology,Second Xiangya Hospital, Central South University, Changsha, CHN
6Department of Hematology, Shantou central Hospital, shantou, China
7Department of Hematology, Hainan Cancer Hospital, Haikou, China
8Department of Hematology, Shenzhen Sixth People's Hospital (Nanshan Hospital), Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, China, Shenzhen, China
9Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China
10epartment of Hematology, the First Affiliated Hospital, Medical College of Shantou University, shantou, China
11Department of Hematology, Shenzhen Luohu People’s Hospital, The Third Affiliated Hospital of Shenzhen University, shenzhen, China
12Department of Hematology, Xiangya Hospital; Central South University, changsha, China
13Department of Hematological, Foshan Hospital of Traditional Chinese Medicine, Foshan, China
14Department of Hematology, Hainan General Hospital, Hainan Medical University, Haikou, China
15Department of Hematology, Shenzhen Hospital, Southern Medical University, shenzhen, China
16Yunnan Province First People's Hosp., Kunming, China
17Department of Hematology, Zhuhai People’s Hospital, Zhuhai 519000, China, Zhuhai, China
18The Second Provincial Hospital of Guangdong, Guangzhou, Guangdong, China
19Zhuzhou Central Hospital, Zhuzhou, China
20Department of Hematology, Yuebei people’s Hospital, Shaoguan University Medical College, Shaoguan, China
21Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, GUANGZHOU, China
22State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
23Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Joaquín Martínez-López1,2*, Maria-Victoria Mateos3, Nieves López-Muñoz, MD4*, Maria Alicia Senin Magan, MD5*, Maria Dunia De Miguel, MD6*, Ana López de la Guía, MD7*, Anna Sureda8, Cristina Encinas, MD9*, Diego Conde Royo, MD10*, Laura Rosinol11*, Lucía García Tomás, MD12*, Jose Angel Hernandez-Rivas, MD, PhD13*, Javier Alberto Rojas, MD14*, Adrian Alegre, MD, PhD15, María Jesús Blanchard, MD16*, Fernando Escalante Barrigón, MD17*, Esther González Garcia, MD18*, Belén Iñigo, MD19*, Pilar Bravo Barahona, MD20*, F. Javier Penalver, MD21*, Javier De La Rubia, MD22*, Noemi Fernandez-Escalada, MD23*, Jose Maria Alonso Alonso, MD24*, Joan Bladé, MD, PhD25*, Juan Jose Lahuerta, MD, PhD26*, Javier De La Cruz27* and Jesús F. San-Miguel28

1H12O-CNIO Clinical research unit, CIBERONC, Complutense University, Madrid, Spain
2Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid, Spain
3Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
4Hematology department, Hospital 12 de Octubre, Madrid, Spain
5Institut Català d´Oncologia Badalona, Barcelona, Spain
6Hospital Universitario de Guadalajara, Guadalajara, Spain
7Hospital Universitario La Paz, Madrid, Spain
8Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
9Hospital Gregorio Marañón, Madrid, Spain
10Hematology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
11Hematology, Hematology Department, Hospital Clinic i Provincial, IDIBAPS, Barcelona, Spain
12H.G.U. Morales Meseguer. IMIB-Arrixaca., Murcia, Spain
13Hospital Universitario Infanta Leonor, Madrid, Spain
14Hospital Universitario Virgen del Rocío, Sevilla, Spain
15Hospital Universitario La Princesa, Madrid, Spain
16Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
17Complejo Asistencial Universitario de León, León, Spain
18Hospital Universitario de Cabueñes, Gijón, Spain
19Hospital Universitario Clínico San Carlos, Madrid, Spain
20Hospital Universitario de Fuenlabrada, Fuenlabrada Madrid, ESP
21Hospital Universitario Fundación Alcorcón, Madrid, Spain
22Hospital Universitari i Politècnic La Fe, Catholic University of Valencia, Valencia, Spain
23Hospital Universitario Marqués de Valdecilla, Santander, Spain
24Complejo Asistencial de Palencia, Palencia, Palencia, ESP
25Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
26Hospital Doce de Octubre, CIBERONC, Madrid, Spain
27Hospital Universitario 12 De Octubre, Instituto De Investigación Sanitaria, Madrid, ESP
28Clinica Universidad de Navarra, Centro de Investigación Medica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number, Pamplona, Spain

Eli Muchtar, MD1, Angela Dispenzieri, MD1, Brendan Wisniowski, MD2*, Giovanni Palladini3, Paolo Milani, MD, PhD4, Giampaolo Merlini5*, Stefan Schönland6*, Kaya Veelken, MD7*, Ute Hegenbart, MD8*, Shaji K Kumar, MD1, Efstathios Kastritis, MD9*, Meletios A. Dimopoulos, MD10, Michaela Liedtke, MD11, Ronald Witteles, MD12*, Vaishali Sanchorawala, MD13, Raphael Szalat, MD, PhD14, Heather J Landau, MD15, Erica Petrlik16*, Suzanne Lentzsch, MD, PhD17, Alexander Coltoff, MD18, Joan Bladé, MD, PhD19*, M. Teresa Cibeira20*, Oliver Cohen, MD21*, Darren Foard, MD21*, Ashutosh D. Wechalekar, MBBS MD22 and Morie A. Gertz, M.D.1

1Division of Hematology, Mayo Clinic, Rochester, MN
2National Amyloidosis Centre, London, United Kingdom
3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy, Pavia, ITA
5Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy
6Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
7Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
8Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-W., Germany
9Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
10Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
11Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
12Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA
13Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA
14Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA
15Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
16Memorial Sloan Kettering Cancer Center, New York, NY
17Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
18Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
19Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
20Hospital Clinic of Barcelona, Barcelona, Spain
21National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom, London, United Kingdom
22University College London, London, United Kingdom

Eli Muchtar, MD1, Brendan Wisniowski, MD2*, Giovanni Palladini3, Paolo Milani, MD, PhD4, Giampaolo Merlini, MD5, Stefan Schönland6*, Kaya Veelken, MD7*, Ute Hegenbart, MD8*, Angela Dispenzieri, MD1, Shaji K Kumar, MD9, Nelson Leung, MD10, Efstathios Kastritis, MD11*, Meletios A. Dimopoulos, MD12, Michaela Liedtke, MD13, Ronald Witteles, MD14*, Vaishali Sanchorawala, MD15, Raphael Szalat, MD, PhD16, Heather J Landau, MD17, Erica Petrlik18*, Suzanne Lentzsch, MD, PhD19, Alexander Coltoff, MD20, Joan Bladé, MD, PhD21*, M. Teresa Cibeira22*, Oliver C Cohen, MBBS, BSc, FRCPath23*, Darren Foard, MD24*, Julian D Gillmore25*, Helen J Lachmann25*, Ashutosh D. Wechalekar26* and Morie A. Gertz, M.D.1

1Division of Hematology, Mayo Clinic, Rochester, MN
2National Amyloidosis Centre, London, United Kingdom
3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
4Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
5Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy, Pavia, ITA
6Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
7Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
8Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-W., Germany
9Department of Hematology, Mayo Clinic Rochester, Rochester, MN
10Division of Hematology, Mayo Clinic Rochester, Rochester, MN
11Department of Clinical Therapeutics, National and Kapodistrian University of Athens, ATHENS, Greece
12Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
13Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
14Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA
15Amyloidosis Center, Boston Medical Center Corporation, Boston, MA
16Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA
17Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
18Memorial Sloan Kettering Cancer Center, New York, NY
19Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
20Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
21Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
22Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
23Department of Haematology, University College London Hospitals, London, ENG, United Kingdom
24National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom, London, United Kingdom
25National Amyloidosis Centre, Royal Free Hospital, London, United Kingdom
26University College London and the Royal Free London NHS Foundation Trust, Division of Medicine, Faculty of Medical Sciences, London, United Kingdom

*signifies non-member of ASH